Cargando…
The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridiza...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716762/ https://www.ncbi.nlm.nih.gov/pubmed/26834489 http://dx.doi.org/10.2147/OTT.S95381 |
_version_ | 1782410584149458944 |
---|---|
author | Yu, Wenjun Guo, Rui Qu, Xiaoyan Qiu, Hairong Li, Jianyong Zhang, Run Chen, Lijuan |
author_facet | Yu, Wenjun Guo, Rui Qu, Xiaoyan Qiu, Hairong Li, Jianyong Zhang, Run Chen, Lijuan |
author_sort | Yu, Wenjun |
collection | PubMed |
description | The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridization was applied to detect the 1q21 amplification in 86 Chinese patients with newly diagnosed MM. Amp(1q21) was found in totally 40 of 86 (46.5%) cases, among which 29 with three copies of 1q21 and eleven with at least four copies of 1q21. Further analysis revealed a significant difference of overall survival and progression-free survival among the three arms (P<0.05). Bortezomib could not significantly improve the overall survival for patients with 1q21 amplification (P>0.05). These findings suggest that 1q21 amplification with four copies or more is prognostic factor for adverse outcomes of MM patients. Furthermore, chromosome 1q21 gains predicted a poor overall survival even in those receiving bortezomib-based regimens. |
format | Online Article Text |
id | pubmed-4716762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47167622016-02-01 The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population Yu, Wenjun Guo, Rui Qu, Xiaoyan Qiu, Hairong Li, Jianyong Zhang, Run Chen, Lijuan Onco Targets Ther Original Research The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridization was applied to detect the 1q21 amplification in 86 Chinese patients with newly diagnosed MM. Amp(1q21) was found in totally 40 of 86 (46.5%) cases, among which 29 with three copies of 1q21 and eleven with at least four copies of 1q21. Further analysis revealed a significant difference of overall survival and progression-free survival among the three arms (P<0.05). Bortezomib could not significantly improve the overall survival for patients with 1q21 amplification (P>0.05). These findings suggest that 1q21 amplification with four copies or more is prognostic factor for adverse outcomes of MM patients. Furthermore, chromosome 1q21 gains predicted a poor overall survival even in those receiving bortezomib-based regimens. Dove Medical Press 2016-01-12 /pmc/articles/PMC4716762/ /pubmed/26834489 http://dx.doi.org/10.2147/OTT.S95381 Text en © 2016 Yu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Yu, Wenjun Guo, Rui Qu, Xiaoyan Qiu, Hairong Li, Jianyong Zhang, Run Chen, Lijuan The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population |
title | The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population |
title_full | The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population |
title_fullStr | The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population |
title_full_unstemmed | The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population |
title_short | The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population |
title_sort | amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a chinese population |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716762/ https://www.ncbi.nlm.nih.gov/pubmed/26834489 http://dx.doi.org/10.2147/OTT.S95381 |
work_keys_str_mv | AT yuwenjun theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT guorui theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT quxiaoyan theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT qiuhairong theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT lijianyong theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT zhangrun theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT chenlijuan theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT yuwenjun amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT guorui amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT quxiaoyan amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT qiuhairong amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT lijianyong amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT zhangrun amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation AT chenlijuan amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation |